MENU
+Compare
BCTX
Stock ticker: NASDAQ
AS OF
May 8 closing price
Price
$3.18
Change
-$0.09 (-2.75%)
Capitalization
21.65M

BCTX Briacell Therapeutics Corp NEW Forecast, Technical & Fundamental Analysis

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company... Show more

BCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BCTX with price predictions
May 08, 2025

BCTX's Stochastic Oscillator stays in oversold zone for 8 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for BCTX crossed bullishly above the 50-day moving average on April 16, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BCTX advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 132 cases where BCTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BCTX moved out of overbought territory on April 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 01, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BCTX as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BCTX turned negative on May 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

BCTX moved below its 50-day moving average on May 01, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BCTX broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. BCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.431) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (253.449).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BCTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BCTX is expected to report earnings to fall 55.84% to -34 cents per share on September 21

Briacell Therapeutics Corp NEW BCTX Stock Earnings Reports
Q2'23
Est.
$-0.34
Q1'23
Missed
by $0.41
Q4'22
Beat
by $0.26
Q3'22
Missed
by $0.74
Q2'22
Missed
by $0.11
The last earnings report on March 16 showed earnings per share of -76 cents, missing the estimate of -35 cents. With 264.15K shares outstanding, the current market capitalization sits at 21.65M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
235 - 15th Street
Phone
+1 604 921-1810
Employees
12
Web
https://www.briacell.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SITM188.5022.30
+13.42%
SiTime Corp
MYNZ2.550.11
+4.51%
Mainz Biomed N.V.
SSBK35.531.03
+2.99%
Southern States Bancshares
TROW92.661.24
+1.36%
T Rowe Price Group
EFC12.940.16
+1.25%
Ellington Financial

BCTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BCTX has been loosely correlated with SNPX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if BCTX jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCTX
1D Price
Change %
BCTX100%
-2.75%
SNPX - BCTX
35%
Loosely correlated
+1.67%
KROS - BCTX
32%
Poorly correlated
+2.26%
MDGL - BCTX
30%
Poorly correlated
+0.25%
AXON - BCTX
30%
Poorly correlated
+14.13%
LSB - BCTX
30%
Poorly correlated
N/A
More